Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.25 -2.8%	$6.63	$4.34 ▼ $12.38	$389.18M	0.46	215,048 shs	86,880 shs
CNTB Connect Biopharma	$2.03 +15.1%	$1.68	$0.51 ▼ $2.86	$112.95M	-0.09	114,082 shs	155,053 shs
CRVS Corvus Pharmaceuticals	$5.70 +5.3%	$4.48	$2.54 ▼ $10.00	$425.01M	0.42	793,062 shs	374,831 shs
KMDA Kamada	$6.94 -1.2%	$7.47	$5.17 ▼ $9.15	$398.54M	0.93	128,540 shs	18,563 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-0.16%	-0.62%	-5.30%	+10.10%	-16.82%
CNTB Connect Biopharma	-1.12%	+1.73%	+0.57%	+125.12%	+72.55%
CRVS Corvus Pharmaceuticals	-1.64%	+2.27%	+19.69%	+42.37%	+31.95%
KMDA Kamada	-1.54%	-0.43%	-6.52%	+2.93%	+22.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.714 of 5 stars	3.6	0.0	2.3	2.5	0.0
CNTB Connect Biopharma	3.3229 of 5 stars	3.8	5.0	2.5	2.5	0.0
CRVS Corvus Pharmaceuticals	3.2246 of 5 stars	3.5	2.0	3.7	3.3	0.6
KMDA Kamada	4.7582 of 5 stars	3.3	5.0	4.1	1.7	4.4

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.11	Buy	$22.00	251.94% Upside
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	245.68% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	163.39% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	87.45% Upside

Current Analyst Ratings Breakdown

Latest CNTB, CRVS, KMDA, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AURA Aura Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
8/13/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.81 per share	N/A
CNTB Connect Biopharma	$1.97M	57.42	N/A	N/A	$1.28 per share	1.58
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
KMDA Kamada	$160.95M	2.48	$0.48 per share	14.50	$4.52 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.96	N/A	N/A	N/A	N/A	-64.44%	-54.24%	11/11/2025 (Estimated)
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
KMDA Kamada	$14.46M	$0.34	20.38	21.67	0.76	11.22%	7.41%	5.18%	11/12/2025 (Estimated)

Latest CNTB, CRVS, KMDA, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.39	12.39
CNTB Connect Biopharma	0.01	7.24	7.24
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
KMDA Kamada	N/A	4.00	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CNTB Connect Biopharma	58.72%
CRVS Corvus Pharmaceuticals	46.64%
KMDA Kamada	20.38%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
CNTB Connect Biopharma	22.60%
CRVS Corvus Pharmaceuticals	28.50%
KMDA Kamada	36.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	62.12 million	58.21 million	Not Optionable
CNTB Connect Biopharma	110	55.72 million	43.13 million	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable

CNTB, CRVS, KMDA, and AURA Headlines

Recent News About These Companies

Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety

August 27 at 3:12 PM | seekingalpha.com

Kamada (NASDAQ:KMDA) Stock Crosses Below 200-Day Moving Average - Here's What Happened

August 24, 2025 | marketbeat.com

Kamada Ltd. (NASDAQ:KMDA) Sees Significant Decline in Short Interest

August 20, 2025 | marketbeat.com

3 Reasons Growth Investors Will Love Kamada (KMDA)

August 19, 2025 | msn.com

Kamada (NASDAQ:KMDA) Releases Earnings Results, Beats Expectations By $0.04 EPS

August 17, 2025 | marketbeat.com

HC Wainwright Has Strong Forecast for Kamada FY2025 Earnings

August 17, 2025 | marketbeat.com

Kamada Ltd. (NASDAQ:KMDA) Q2 2025 Earnings Call Transcript

August 14, 2025 | insidermonkey.com

What Makes Kamada (KMDA) a New Buy Stock

August 14, 2025 | msn.com

KMDA vs. ILMN: Which Stock Is the Better Value Option?

August 14, 2025 | zacks.com

Kamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...

August 14, 2025 | finance.yahoo.com

Kamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to Say

August 14, 2025 | msn.com

Kamada (KMDA) Q2 Earnings Top Estimates

August 13, 2025 | zacks.com

Kamada Q2 2025 Earnings Preview

August 12, 2025 | msn.com

3KMDA : An Overview of Kamada's Earnings

August 12, 2025 | benzinga.com

Kamada Ltd.: Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

August 11, 2025 | finanznachrichten.de

Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

August 11, 2025 | finance.yahoo.com

Kamada’s Houston Plasma Center Gains FDA Approval

August 11, 2025 | tipranks.com

Exploring Analyst Estimates for Kamada (KMDA) Q2 Earnings, Beyond Revenue and EPS

August 8, 2025 | msn.com

Y.D. More Investments Ltd Sells 168,568 Shares of Kamada Ltd. (NASDAQ:KMDA)

August 8, 2025 | marketbeat.com

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

August 6, 2025 | globenewswire.com

Kamada (KMDA) to Release Quarterly Earnings on Wednesday

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, CRVS, KMDA, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.25 -0.18 (-2.78%)

As of 03:52 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Connect Biopharma NASDAQ:CNTB

$2.02 +0.27 (+15.06%)

As of 03:51 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.70 +0.29 (+5.27%)

As of 03:51 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Kamada NASDAQ:KMDA

$6.94 -0.09 (-1.21%)

As of 03:48 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time